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Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. Although treatments have improved,
development of novel therapies for patients with CVD remains a major research goal. Apoptosis, necrosis, and autophagy occur
in cardiac myocytes, and both gradual and acute cell death are hallmarks of cardiac pathology, including heart failure,
myocardial infarction, and ischemia/reperfusion. Pharmacological and genetic inhibition of autophagy, apoptosis, or necrosis
diminishes infarct size and improves cardiac function in these disorders. Here, we review recent progress in the ﬁelds of
autophagy, apoptosis, and necrosis. In addition, we highlight the involvement of these mechanisms in cardiac pathology and
discuss potential translational implications.
Cell Death and Disease (2011) 2, e244; doi:10.1038/cddis.2011.130; published online 22 December 2011
Subject Category: Internal Medicine
Cardiac Myocyte Death in the Pathogenesis of Disease
The heart is an organ with limited capacity for regeneration
and repair; hence, it is susceptible to numerous stresses and
must respond to these insults in order to adapt to ever-
changingworkloaddemands.Celldeath,eitherprogressiveor
acute,isa hallmark characteristicofvarious cardiac diseases,
including heart failure (HF), myocardial infarction (MI), and
ischemia/reperfusion (I/R; Figure 1).
1 Now, at the turn of the
21st century, however, cardiovascular disease (CVD) still
accounts for more than one-third of all human mortality and
remains the leading cause of death worldwide. All three types
of cell death, autophagic cell death, apoptosis, and necrosis,
have been observed during progression of heart disease.
1
Autophagy
One of the key cellular pathways that mediate stress-induced
adaptation and damage control is macroautophagy (termed
autophagy in this review). Autophagy is a highly conserved
process of delivery of intracellular components, including
mitochondria and long-lived macromolecules, via a double-
membrane structure (autophagosome) to lysosomes for
degradation.
2 In eukaryotic cells
2 and in cardiac myocytes,
3
starvation/nutrient deprivation, hypoxia, reactive oxygen
species (ROS), damaged organelles, and protein aggregates
have each been shown to induce autophagy in a mammalian
target of rapamycin (mTOR)-dependent process. Similarly,
mTOR-independent autophagy has been reported; cytokines,
which do not exist in yeast, converge on type III phosphati-
dylinositol 3-kinase to induce autophagy.
4
Autophagy in Response to Ischemia and I/R
More than 95% of the energy required for cardiac myocyte
function is derived from oxidative phosphorylation. Interrup-
tion of blood ﬂow to the myocardium disrupts oxygen supply,
triggering rapid declines in ATP and increased AMP/
ATP ratios. Autophagy, as a pro-survival mechanism that
replenishes energy under stress conditions, is activated.
Ischemia/hypoxia induces autophagy in vivo and in vitro in
most,
5,6 although not all,
7 studies. The two pathways
responsible for ischemia/hypoxia-induced autophagy involve
either BNIP3
8 or AMPK.
9 In a mouse model expressing
dominant-negative AMPK in cardiac myocytes, the auto-
phagicresponsetoischemiawasattenuated,leadingtolarger
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9 If ischemia is prolonged, the
autophagic response becomes dysfunctional, as evidenced
by the existence of impaired autolysosomes.
During reperfusion, autophagy is upregulated further, even
though the delivery of oxygen and nutrients is restored and
AMPK is rapidly inactivated.
5,10 The continued activation
of autophagy during reperfusion is qualitatively different than
that in ischemia, especially in terms of mechanisms of
induction.Stimulators, suchasoxidativestress, mitochondrial
damage/BNIP3, endoplasmic reticulum stress, and calcium
overload, likely have more important roles in maintaining
autophagy at a higher level during reperfusion.
11 Although the
available evidence is consistent that autophagy is protective
under conditions of mild-to-moderate ischemia, the same
cannot be said of autophagy elicited by reperfusion. Indeed,
upregulation of autophagy can be either beneﬁcial or
detrimental in the context of I/R.
5,10
Recent evidence reveals that autophagosome clearance is
impaired in I/R. Ischemia induces a decline in the levels
of LAMP2, a protein critical for autophagosome–lysosome
fusion, mediated by ROS-induced activation of serine
and cysteine proteases; reperfusion induces upregulation of
Beclin 1, which further impairs autophagosome processing,
culminating in increased ROS generation, mitochondrial
permeabilization, and cardiomyocyte death.
12 More investi-
gation is needed to clarify when and how elevated autophagy
may be pro-survival to cardiac myocytes subjected to
reperfusion injury.
Autophagy in Response to MI
There is limited information regarding autophagy in the
context of MI. The most likely region where autophagy might
be important is the sublethally injured, peri-infarct zone.
In addition, autophagy may contribute to the more global
process of postinfarction remodeling. Activation of AMPK by
metformin blunted development of HF induced by MI, and
inhibiting mTOR led to reduced remodeling and improved
cardiac function after MI.
13 Moreover, STAT1 deﬁciency is
protective by enhancing autophagy in an ex vivo model of
MI.
14However,thepossibleroleofautophagicﬂuxintheheart
was not examined in these studies. Although these data
suggestthatagentsknowntoregulatepathwaysthataugment
autophagy were protective, direct evidence is lacking regard-
ing the speciﬁc role that autophagy has in MI.
Autophagy in Response to Cardiac Hypertrophy and HF
In response to hemodynamic stress, such as pressure
overload, the heart hypertrophies. Cardiac hypertrophy (CH)
is thought to be an adaptive process initially; however, it
becomes detrimental to cardiac function if left unchecked.
CH is a major, independent risk factor for systolic dysfunction
and clinical HF.
15 In HF patients, cardiac myocyte death with
autophagic features occurred at a rate of 0.03% in human-
dilated cardiomyopathy (C), as compared with 0.002% for
apoptotic cell death.
16 Together, these lines of evidence
support the notion that autophagy participates in the
pathogenesis of HF. The speciﬁc role of autophagy, however,
in the pathogenesis of CH and HF-related remodeling is less
clear.
The strongest evidence that autophagy facilitates develop-
ment of pathological hypertrophy derives from genetic
manipulations of the core autophagic machinery in mouse
models.
17,18Incontrast,severallinesofevidencehighlightthe
fact that autophagy can have an anti-hypertrophic role.
The latter notion, however, requires additional corroboration,
as it relies largely on indirect pharmaceutical manipulations of
autophagy via upstream pathways.
19–21 Here, we will brieﬂy
detail the studies supporting both concepts (see Figure 2 for
an overview of major regulators of autophagy targeted in
these studies).
CH was attenuated in Beclin 1 haploinsufﬁcient hearts.
Overexpression of Beclin 1 led to exacerbated hypertrophic
growth in response to pressure overload.
18 Importantly,
a recent study by our group suggested that autophagy is
necessary for the process of CH. In this study, moderate
pressure overload that induces CH also activated autophagy,
and blocking this process inhibited pathological heart remo-
deling. RNAi-dependent knockdown of ATG5 and Beclin 1
attenuated the growth response induced by hypertrophic
agonists.
17
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Figure 1 Aging, stress, and cell death progression. The cell injury marker
troponin T increased during aging, as well as with different CVDs (de Lemos et al.)
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Figure 2 Schematic overview of the regulators of autophagy described in this
section: Atg5 and Beclin 1 – components of the core autophagic machinery; mTOR
and Raptor are components of the mTOR complex 1, an upstream repressor of
autophagy; rapamycin – an inhibitor of mTOR (activates autophagy by releasing
mTOR-mediated inhibition)
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Cell Death and DiseaseConversely, inhibition of mTOR, an upstream repressor of
autophagy, blunts CH, both clinically and in an animal
model.
20,22 However, the status of autophagy in these
patients and animal hearts was not tested following treatment
with rapamycin.
20,22 Inactivation of cardiac mTOR was also
associated with marked elevation of apoptosis and declines in
myocardial function and accelerated progression to HF.
21
This could be rescued by deletion of a direct target of mTOR,
4E-BP1, although without notable changes in autophagy,
suggesting that this process may not be a major contributor to
the development of HF in these animals; rather, inhibition
of protein synthesis may be the primary mechanism.
In accordance, cardiomyocyte-speciﬁc inactivation of Raptor,
a component of the mTOR complex 1, induces dilated C and
high mortality within 6 weeks, with increases in apoptosis and
autophagy. This evidence demonstrates a speciﬁc role of
mTOR in preserving cardiac function.
19
An emerging concept of an optimal, ‘adaptive zone’ of
autophagic activation suggests an explanation of all this
seemingly conﬂicting evidence. According to this concept, too
much or too little autophagy may lead to increased hyper-
trophy and heart dysfunction. Supporting this, the conditional
lossoffunctionofAtg5inadultmiceledtorapidprogressionto
hypertrophy and cardiac dysfunction in the absence of
pressure overload.
23
It may seem counterintuitive that blocking a catabolic
pathway inhibits cardiac growth. However, cardiac myocytes
are not quiescent structures; their components, including
sarcomeres and mitochondria, are highly dynamic and
constantlyturningover.Indeed,thephenomenonofactivation
of both anabolic and catabolic processes during development
of CH was observed long ago. However, the speciﬁc role of
autophagy as a part of the catabolic process in CH has only
recentlystartedtosurface.Oneday,itmayemergeasatarget
for CH and HF therapy.
Translational Implications in Cardiac Autophagy
Modulation of the autophagic pathway may represent a future
therapeutic target in heart disease. However, the complex
nature of autophagic mechanisms and the lack of autophagy-
speciﬁc inducing and blocking agents all contribute to limiting
its therapeutic application. Agents such as metformin and
rapamycin, an AMPK activator and mTOR inhibitor, respec-
tively, have been tested in clinical settings for purposes other
than autophagy. Metformin is used commonly in patients with
diabetes, and its use diminishes all-cause mortality and MI.
24
More recently, animal models of ischemia and I/R have
reported beneﬁcial effects of metformin by decreasing infarct
size and blunting HF.
25 Other medications used in MI, such as
b-blockers (e.g., propranolol) and calcium channel blockers
(e.g., verapamil), were examined more than 20 years
ago.
26,27 These studies found that the b-adrenergic agonist
isoproterenol inhibited autophagy;
27 and propranolol and
verapamil had the opposite effect.
26 These actions, however,
were rather short lived, lasting only 10min.
26,27 The long-term
impact on autophagy of b-blockers and calcium channel
antagonists are unknown and potentially clinically relevant, as
patients typically use them chronically to control blood
pressure and symptoms from ischemic heart disease.
On the other hand, the a1-adrenergic receptor agonist
phenylephrine increases cardiac myocyte autophagy.
17
Autophagy can be activated by caloric restriction.
28 In
animal models, caloric restriction attenuates age-related
changes in the heart, including hypertrophy, myocardial
ﬁbrosis, shifts in myosin isoform composition, histological
changes, apoptosis, and the deterioration of chronotropic and
inotropic responses to adrenergic stimulation.
28 In humans,
echocardiographic studies have shown that caloric restriction
improves diastolic function in healthy nonobese humans in
conjunction with reductions in indices of myocardial stiff-
ness.
28Itisapparentthatmore researchisneededbeforeany
conclusion can be drawn regarding the exact role autophagy
has in ischemia and I/R, so that agents speciﬁcally designed
as autophagy inducers or inhibitors can be considered
clinically.
Recent work has provided insight into how autophagy
contributes to CH. Evidence supports the notion that activa-
tion of autophagy is required for both myocyte growth and to
maintain homeostasisin an enlarged,hypertrophied myocyte.
Histone deacetylase (HDAC) inhibitors suppress the mala-
daptive autophagic response, contributing to their anti-
hypertrophic effects and leading to improved cardiac func-
tion.
17 Indeed, increased autophagic activity may be a
universal feature of C, including chemotherapy-induced C
and HF. The clinical relevance of HDAC inhibitors and
autophagy in the heart is potentially signiﬁcant, as these
agents are currently used in patients as cancer chemother-
apy. Conceivably, they are in a unique position to kill cancer
cells and protect the heart at the same time.
In summary, the role of autophagy is intricate, and its
contribution to heart disease is complex. Many aspects are
stilldebatedandactivelyinvestigated.However,maintenance
of a balance of autophagy is critical, not too much and not too
little (Figure 3).
Apoptosis
Apoptosis is mediated by two pathways, the extrinsic and the
intrinsic pathways, and both have been described in cardiac
myocytes.
1 The extrinsic apoptotic pathway can be triggered
by FAS ligand, tumor necrosis factor (TNF)-a, or TRAIL. Both
FAS and TNF receptor I are expressed in cardiac myocytes
and have been implicated in cardiovascular pathology.
1
TRAIL has also been reported to be released by cardiac
myocytes,
29 but no further information is available about
TRAIL and the heart. Cardiac myocyte-speciﬁc overexpres-
sionofTNF-aintransgenicmiceprovokeddilatedCandHF,
30
suggesting that activation of the death receptor pathway by
TNF-a is harmful to the heart (Figure 4).
The mitochondrion is the primary organelle involved in
mediating the intrinsic apoptotic pathway. In cardiac myo-
cytes,mitochondriaarelocatedatintermyoﬁbrillarspacesand
underneath the sarcolemma. This strategic distribution of
mitochondria allows for efﬁcient ATP supply to the high-
energy demand, continuously contracting cardiac myocyte.
However, because mitochondria can also contribute to cell
deathinresponsetomultiplestresses,cardiacmyocyteshave
developed special strategies to achieve strict control over the
intrinsic apoptotic pathway.
1,31 Cardiac myocytes express
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Cell Death and Diseasevarious members of the BCL2 family, several of which are
transcriptionally regulated in heart disease, including anti-
apoptotic and pro-apoptotic BCL2 proteins.
32
Cardiac myocytes express low levels of Apaf1, and a
consequence of this low Apaf1 activity is the engagement of
strict control of caspase (casp) activation by endogenous
XIAP.
33 In fact, direct microinjection of cytochrome c (cyto c)
into cardiac myocytes was not sufﬁcient to induce apopto-
sis.
33 This observation is consistent with studies showing
substantial translocation of cyto c into the cytosol, without
much detectable apoptosis in human cardiomyopathic
hearts.
34 Downregulation of XIAP and cIAP1/2 in cardiac
myocytes within the failing myocardium has been suggested
to contribute to increased cardiac myocyte apoptosis.
34
Transgenic mice overexpressing cIAP2 had reduced infarct
size and fewer TUNEL-positive cells after I/R.
35 IAPs can also
be inhibited by SMAC/DIABLO and OMI/HTRA2, and inhi-
bition of OMI/HTRA2 reduced apoptosis and infarct size in rat
after I/R.
36
Mitochondria in Cardiac Myocyte Apoptosis
It has been suggested that activation of the mitochondrial
apoptotic pathway leading to executioner casp activation is
relevant in heart injury.
1 The notion of participation of casp
activation in adult cardiac myocyte apoptosis emerged from
studies using immunoﬂuorescence microscopy
16 and casp
inhibitors.
37 Bahi et al.
38 demonstrated that cardiomyocyte
levels of all casps decrease with age, and they are very low in
adult cardiac cells. Recently, Bae et al.
39 reported that
apoptosis can be induced in the heart lacking casp activation
via casp-independent pathways, probably through apoptosis-
inducing factor (AIF). Both the intrinsic and extrinsic pathways
can be inhibited by the cytoprotective protein apoptosis
repressor with caspase recruitment domain (ARC). ARC
inhibits the extrinsic pathway by interacting with casp 8 and
components of the death-inducing signaling complex, such as
FADD, whereas inhibition of the intrinsic pathway is mediated
by blocking BAX activation and mitochondria translocation.
40
AIF is anchored by its N terminus to the mitochondrial inner
membrane, with its C terminus oriented toward the inter-
membrane space. AIF is required for oxidative phosphoryla-
tion and for the assembly and/or stabilization of respiratory
complex I.
41 Upon induction of apoptosis, AIF is cleaved and
released into the cytosol, where it translocates to the nucleus
and mediates chromatin condensation and large-scale DNA
fragmentation.
41 However, this well-known pro-apoptotic
action of AIF is in conﬂict with the observation that AIF is
essential for the maintenance of normal heart function and its
inactivationresultsindilatedC.
42Moreover,cardiacmyocytes
isolated from a mouse model with 80% reduction in AIF levels
manifested increased cell death induced by oxidative stress,
and the hearts of these mice displayed enhanced ischemic
damageafterinvivoI/R.
43Althoughithasbeendescribedthat
AIF is released from cardiac myocyte mitochondria during I/R,
its contribution to I/R-induced apoptosis was discounted.
38
However, AIF has been implicated in cardiac myocyte death
induced by oxidative stress and HF.
44
Endonuclease G (Endo G) is a nuclear-encoded endonu-
clease localized to the intermembrane space of mitochondria.
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Figure 4 Apoptotic pathway in cardiac myocytes. In the extrinsic pathway,
death receptor activation by a death ligand induces death-inducing signaling
complex(DISC)formationandcasp8activation,whichinturnactivatescasp3.This
pathway can also activate the intrinsic pathway by the proteolysis of BID to t-BID by
casp 8 and interaction of t-BID with BAX in the mitochondria. Pro-apoptotic BAX/
BAK induces cyto c, Smac/DIABLO, AIF, and Endo G release from the
mitochondria. Cyto c with Apaf1 and casp 9 form the apoptosome with activation
ofcasp9.CaspactivityisregulatedbytheendogenouscaspinhibitorXIAP.Cardiac
myocytes are naturally resistant to apoptosis due to their low-level expression of
Apaf1 and casps and high levels of XIAP
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Figure 3 The Goldilocks rule of autophagy in heart disease. Autophagy is a
dynamic process. The relationship between autophagy and heart disease is
complex. Although basal autophagy is critical to maintain cellular and whole-body
homeostasis, both increases and decreases in autophagy to excessive degree can
be maladaptive. In CH, HF, and I/R, autophagic ﬂux is abnormally elevated,
contributing to cardiac dysfunction. With aging, Pompe disease, and Danon
disease, autophagic activity and processing are attenuated, perturbing cellular
homeostasis and contributing to cardiac disease. Animal models havebeen studied
extensively to evaluate the role of autophagy in heart disease with either increases
(Beclin 1 tg) or decreases (Atg5 KO, Beclin 1 het) in autophagic activity
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Cell Death and DiseaseIn cardiac myocyte apoptosis, Endo G translocates to the
nucleus, where it cleaves DNA. In heart and cultured cardiac
myocytes, Endo G has a role in I/R-mediated cell death.
38
Activation of the intrinsic pathway by the extrinsic apoptotic
pathway can take place through casp-8-dependent cleavage
ofBCL2-interactingprotein(BID)totruncatedBID(t-BID).The
C-terminal fragment of t-BID subsequently translocates to the
mitochondrialoutermembrane,whereitpresumablyactivates
the intrinsic pathway. This pathway is operative in the heart.
1
Mitochondrial Dynamics and Apoptosis
Mitochondria exist as a complex, interconnected, and highly
dynamic network characterized by the ongoing and counter-
balanced events of mitochondrial fusion and ﬁssion.
45
Mitochondrial ﬁssion is regulated by DRP-1 and FIS1,
whereas mitochondrial fusion is controlled by mitofusins
1/2 (MFN1/2) and OPA1.
45 Changes in the mitochondrial
morphology of cardiac myocytes have been reported in
several heart diseases.
46 Fragmentation of the mitochondrial
network in response to apoptotic stimuli is a frequent ﬁnding
observed in cardiac myocytes.
47 Loss of integrity of the
mitochondrial membrane is mediated by a complex process
that involves DRP-1, MFN2, and the pro-apoptotic protein
BAX.
45,46 Decreases in the abundance of MFN2 is associated
with an increase in mitochondrial fragmentation and cyto
c release, pointing to a protective role of MFN2 against
apoptotic death.
47
Recently, emerging evidence suggests that the unfolded
protein response (UPR) has important roles in pressure
overload-triggered HF.
48 UPR markers, including GRP78,
calreticulin and GRP94, are signiﬁcantly upregulated in
mouseheartinthesettingofpressureoverload.
48Angiotensin
II administration can induce ER stress and apoptosis
in cultured cardiomyocytes. Furthermore, CHOP activation
in pressure overload contributes to CH and HF.
49 Fu et al.
49
showed that CHOP-deﬁcient animals manifested less CH,
ﬁbrosis, and cardiac dysfunction in the setting of pressure
overload. These studies highlight the critical role of ER stress
in CH and HF.
Apoptosis in HF
Apoptosis is rare in normal human myocardium, with a
reported prevalence of approximately one TUNEL-positive
cardiac myocyte per 10000–100000, that is, 0.01–0.001%. In
human failing hearts of New York Heart Association
class III–IV, apoptotic cells are detectable in the range of
0.12–0.70%.
50 In all reported cases, apoptosis levels were
substantially lower than 1%. Because the limited ability of
cardiac myocytes to proliferate, low levels of apoptosis can
still have profound effects. Mani
51 has postulated that an
apoptotic rate of 0.1% would be expected to result in a B37%
loss in cardiac myocyte number over a year. This issue was
addressed by generating transgenic mice with cardiac
myocyte-speciﬁc expression of an inducible casp 8.
52 These
transgenic mice developed severe, dilated C over 8 weeks
and died within 2–6 months, manifesting disease progression
that was markedly accelerated as compared with healthy
wild-type mice that exhibited apoptotic rates of B0.002%.
52
This ﬁnding suggests that a very low, albeit elevated,
rate of apoptosis can be an important component of HF
pathogenesis.
Apoptosis in MI and I/R
Because of the intrinsically low levels of Apaf1 and casps in
cardiac myocytes, nonmyocyte cells within the heart may be
more susceptible to apoptosis. This, in turns, complicates the
studyofcardiacmyocyteapoptosisinwholeheart.Permanent
coronary occlusion induced maximum cardiac myocyte
apoptosis at 4.5h, whereas necrosis peaked at 24h.
53
Reperfusion appeared to accelerate the timing of apoptosis
as compared with permanent occlusion.
54
Mice that lack FAS (lpr mice) exhibited a decrease in
cardiac myocyte apoptosis in models of doxorubicin toxicity,
55
as well as marked reductions in infarct size following I/R.
56
However, deletion of either TNFR1 or TNFR2 does not affect
infarct size. In contrast, deletion of both together resulted in
signiﬁcantly larger infarcts following permanent coronary
occlusion.
57 These results suggest that FAS, and not TNFR,
is the major mechanism for activating the extrinsic apoptotic
pathway during MI.
Cardiac myocyte-speciﬁc overexpression of BCL2 sub-
stantiallyreducesinfarctsize,cardiacmyocyteapoptosis,and
cardiac dysfunction following I/R.
58 BAX deﬁciency reduces
infarct size and cardiac dysfunction following I/Rand following
MI in mice.
59 Targeted deletion of PUMA reduced infarct size
B50% in an ex vivo Langendorff I/R model.
60 Together, these
results suggest that the intrinsic apoptosis pathway also has a
central role in MI.
Translational Implications of Cardiac Apoptosis
To date, no clinical trial has been attempted to speciﬁcally
block or inhibit apoptotic pathways during MI. However, in
chronic HF, clinical trials have been carried out using
compounds that deplete circulating TNF-a.
61 Etanercept is a
recombinant human-soluble TNF receptor that binds to and
neutralizes circulating TNF-a.
61 Despite encouraging results
in small pilot trials,
61,62 large multicenter trials of etanercept in
moderate-to-severe HF did not demonstrate signiﬁcant
clinical beneﬁt and even suggested that etanercept may
adversely affect the course of the disease.
61,63
Inﬂiximab is a recombinant human-murine chimeric mono-
clonal antibody that speciﬁcally binds to and neutralizes
TNF-a.
64 Inﬂiximab improved left ventricular function and
limited HF in TNF-a overexpressing transgenic mice.
64
However, the ATTACH trial did not detect HF improvement,
but rather uncovered a signal for adverse events in patients
with moderate to severe HF.
61,65 These disappointing results
might be explained by the dual action of TNF-a: short-term
beneﬁcial but long-term harmful effects. More encouraging
results have been obtained with pentoxifylline, a xanthine-
derived compound that directly modulates TNF-a mRNA
expression,
66 (as opposed to neutralizing circulating TNF-a).
A single-center, placebo-controlled trial of pentoxifylline
reported improvement in left ventricular performance in
idiopathic dilated C.
67 A large multicenter trial is warranted.
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Cell Death and DiseaseNecrosis
Necrosis is marked by distinct morphological changes,
including cell swelling, plasma membrane damage, loss of
ATP, and organelle swelling. Disruption of cell integrity and
release of cellular contents trigger a secondary inﬂammatory
response, with potential pathological consequences.
1 Necro-
sis is mainly caused by physical or chemical trauma to the cell
and has long been considered as passive and accidental cell
death.
68Recently,however,emergingevidencesuggeststhat
a proportion of necrosis is regulated by serial signaling events
in a controlled and orchestrated manner. Several terms have
been introduced to describe this form of necrosis, such as
programmed necrosis, casp-independent cell death, and
necroptosis.
69 A number of mechanisms has been proposed
to explain the initiation and execution of necrosis, including
death receptors, ROS, Ca
2þ, and mitochondrial permeability
transition pore (MPTP) opening (Figure 5).
68,70
Necrosis in HF
A characteristic feature of HF is progressive dropout of
cardiacmyocytesanddevelopmentofcardiacdysfunction.As
noted above, early studies suggested that apoptosis serves
as one critical factor contributing to cell demise in end-stage
HF. However, later observations suggested that necrosis is
more prominent in failing human heart, contributing several
fold more to disease pathogenesis than apoptosis in both
men and women.
71 Mechanistically, sustained Ca
2þ stress,
together with persistent activation of adrenergic receptors,
triggers necrotic cell death. Using inducible overexpression of
the L-type Ca
2þ channel (LTCC) speciﬁcally in cardiac
myocytes, Nakayama et al.
72 found that an increase of LTCC
activitypromotedprogressivecelldeath,andcoadministration
of an adrenergic receptor agonist ampliﬁed this process.
Importantly, cardiac myocytes were protected from cell death
when cyclophilin D is absent, suggesting the MPTP and
necrosis are involved.
73,74 In contrast, forced expression of
the anti-apoptotic protein BCL2 did not rescue cell death by
Ca
2þ overloading. These data suggest strongly that necrosis
contributes to the progression of HF, and that Ca
2þ handling
and MPTP opening may be critically involved.
Necrosis in MI
During MI, activation of anaerobic glycolysis to provide
ATP leads to accumulation of H
þ and acidosis. Ion pumps
on the plasma membrane respond to remove excess H
þ in
exchange of Na
þ. In response to elevated levels of
intracellular Na
þ, the Na
þ/Ca
2þ exchanger operating
in reverse mode is less capable of removing intracellular
Ca
2þ, culminating in increased cytoplasmic Ca
2þ levels. The
mitochondrial Ca
2þ uniporter then transports Ca
2þ into
mitochondria. Increases in Ca
2þ within this organelle induces
Ca
2þ-dependent dehydrogenase activation, declines in
NADH and electron ﬂux through the electron transport chain,
increased ROS, and decreases in ATP levels. As Ca
2þ
uptake into mitochondria dissipates mitochondrial membrane
potential, eventually the increase in matrix Ca
2þ reaches a
plateau under hypoxic conditions due to limitation of the
proton gradient. Upon reperfusion, however, restoration of
oxygenandATP-generatingcapabilitiesquicklyrecoversATP
levels and mitochondrial membrane potential. These changes
regenerate the required ion gradient for more Ca
2þ entry into
mitochondria, which causes long-lasting opening of MPTP
regulated by cyclophilin D, and mitochondrial swelling leads
ultimately to cellular necrosis.
1
Some evidence implicates MPTP opening as a mechanistic
link between myocyte necrosis and I/R injury. Involvement of
MPTP in cardiac I/R responses was elegantly illustrated by
the Molkentin and Tsujimoto groups.
73,74 Using similar
genetic approaches, they found that lack of cyclophilin D
protected cardiac myocytes from Ca
2þ overload-induced cell
death in vitro. Infarct size and lactate release from the heart
were dramatically reduced in the mutant animals after I/R.
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Figure 5 Necrosis pathways in cardiac myocytes. During certain cardiac
pathologies, such as I/R, the action of cellular pumps is inhibited by ATP depletion,
thereisaconsequentincreaseinH
þ andNa
þ,andthesodium-calciumexchanger
(NCX)operatesinreversemanner.IncreasedcytoplasmicCa
2þ leadstoincreased
Ca
2þ in the mitochondrial matrix along with elevated levels of ROS, culminating in
MPTP opening, and necrosis. On the other hand, mitochondrial swelling and
mitochondrial membrane rupture also produce necrosis. Moreover, increased H
þ
in the cytoplasm and inactivation of H
þ pumps elicit declines in lysosomal pH,
which results in overactivation of proteases such as cathepsins. The massive entry
of water results in lysosomal swelling, membrane rupture, and release of proteases
into the cytoplasm,which together with other activatedproteases, such as calpains,
digest different substrates, including cytoskeletal proteins, contributing to necrosis.
Activationofdeathreceptors,suchastheTNF-areceptor,representsothernecrosis
pathways in cardiac myocytes under certain conditions such as HF. The activation
of these receptors could lead to the activation of receptor-interacting protein (RIP),
increased ROS, and necrosis. The massive inﬂow of water into the cell by the
osmotic imbalance ultimately leads to cell swelling and rupture of the plasma
membrane
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Cell Death and DiseaseInterestingly, pro-apoptotic protein-induced cyto c release
did not differ between wild-type and knockout mitochondria,
suggesting that cyclophilin D does not have a critical role in
apoptosis.
Translational Implications of Necrosis
Promising work on MPTP opening from in vitro tissue culture
and in vivo animal studies has provided hints regarding
therapeutic targets to protect the heart from necrosis.
Cyclosporin is a potent inhibitor of MPTP. A pilot clinical trial
by Piot et al.
75 found that acute treatment with cyclosporin
upon reperfusion at the time of percutaneous coronary
intervention was associated with reduced infarct size and
reduced creatine kinase and troponin I release. Although
these results are encouraging and suggest that inhibition of
MPTP is key in the protection against necrotic death during
I/R, additional experimental work is needed to determine the
contribution of other targets of cyclosporin, such as calci-
neurin or nitric oxide synthase (NOS), in this cardioprotection.
Necrostatin-1 is a selective inhibitor of necroptosis, a
specialized pathway of programmed necrosis, targeting the
kinase RIP1.
76 In vitro studies using cancer cell lines reported
protective effects of necrostatin-1 in TNF-a induced necrosis.
Morerecently,theroleofnecrostatin-1incardiacI/Rhasbeen
evaluated.
76 A bolus dose of necrostatin-1 inwild-type mice at
the time of coronary reperfusion dramatically reduced infarct
size after I/R injury, whereas no protection was found
in cyclophilin D-deﬁcient animals. Necrostatin-1 may hold
promise for consideration of clinical use.
Table 1 Autophagy, apoptosis, and necrosis interventions
Type Intervention Model Effect Reference
Autophagy Dominant-negative AMPK Transgenic mouse Attenuated autophagic response to ischemia with larger MI
and worse cardiac function
Russell et al.
9
Activation of AMPK with
metformin
Rat Reduction of HF induced by MI Buss et al.
13;Y i net al.
25
STAT1 deﬁciency Transgenic mouse Enhanced autophagy that protects upon reperfusion McCormick et al.
14
Atg5 knockout Transgenic mouse Rapid progression to hypertrophy and cardiac dysfunction
with pressure overload
Nakai et al.
23
Beclin 1 heterozygous
disruption
Transgenic mouse Decreased heart hypertrophy to pressure overload Zhu et al.
18
Beclin 1 overexpression Transgenic mouse Exacerbated heart hypertrophy to pressure overload Zhu et al.
18
Propranolol (b-blocker) and
verapamil (calcium channel
blocker)
Rat Induction of autophagy Bahro and Pfeifer
26
Isoproterenol (b-adrenergic
agonist)
Rat Inhibition of autophagy Pfeifer et al.
27
Phenylephrine (a1-
adrenergic agonist)
Cultured rat
cardiomyocytes
Induction of autophagy Cao et al.
17
Histone deacetylase Cultured rat
cardiomyocytes
Suppression of maladaptive autophagic response Cao et al.
17
Apoptosis Overexpression of cIAP2 Transgenic mouse Reduced infarct size and TUNEL-positive cells after I/R Chua et al.
35
Inhibition of OMI/HTRA2 Rat Reduction of apoptosis and infarct size after I/R Bhuiyan and Fukunaga
36
Caspase inhibition with
YVAD-cmk
Rat Reduced infarct size and TUNEL-positive cells
after I/R
Holly et al.
37
Doxorubicin treatment of
caspase inhibitor CrmA in
overexpressing mice
Transgenic mouse Induction of apoptosis in hearts lacking caspase activation
via caspase-independent pathways, probably by AIF
Bae et al.
39
Cardiac-speciﬁc expression
of inducible caspase 8
Transgenic mouse Presence of 0.023% of apoptosis, with development of
severe dilated cardiomyopathy over 8 weeks and death
after 2–6 months
Wencker et al.
52
FAS knockout Transgenic mouse Decreased apoptosis upon doxorubicin treatment and
reduction of infarct size following I/R
Nakamura et al.
55; Lee
et al.
56
Cardiac-speciﬁc
overexpression of BCL2
Transgenic mouse Reduction of infarct size, apoptosis and cardiac
dysfunction after I/R
Chen et al.
58
BAX knockout Transgenic mouse Reduction of infarct size and cardiac dysfunction following
I/R and MI
Hochhauser et al.
80
PUMA knockout Transgenic mouse Reduction of infarct size in an ex vivo Langendorff
I/R model
Toth et al.
60
Etanercept, a recombinant
human-soluble TNF receptor
Clinical trials Nonsigniﬁcant clinical beneﬁts Balakumar and Singh
61;
Mann et al.
63
Inﬂiximab, a recombinant
chimeric TNF-a-neutralizing
monoclonal antibody
Clinical trials Non-HF improvement and increased adverse effects in
patients with moderate-to-severe HF
Kadokami et al.
64
Necrosis Cyclophilin D knockout Transgenic mouse Resistance to necrotic cell death induced by reactive
oxygen species and Ca
2+ overload and a high level of
resistance to I/R-induced cardiac injury
Baines et al.
73;
Nakagawa et al.
74
Acute treatment with
cyclosporin A, a MPTP
inhibitor, during
percutaneous coronary
angioplasty
Clinical trials Reduction of infarct size and reduced creatine kinase
and troponin I release
Piot et al.
75
Necrostatin-1 Mouse Reduction of infarct size after I/R Lim et al.
76
Abbreviations: HF, heart failure; I/R, ischemia/reperfusion; MI, myocardial infarct
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Type Patent category Therapeutic/Target Remarks Patent number
Necrosis Necrosis inhibitor 4-(4-Chlorobenzyl)-2-(hexahydro-1-methyl-1H-
azepin-4-yl)-1(2h)-phthalazinone
MIS JP63218622
Necrosis inhibitor Potassium channel activator, such as pinacidil
or cromakalim
I/R EP0351767
Necrosis inhibitor 1,4-Benzoxazine derivative such as Na
+/H
+ exchange
inhibitor
MIS, cardiac dysfunction,
myocardial necrosis,
arrhythmia, RI, MI
US5597820
Necrosis inhibitor Benzo[1,4]thiazine derivatives such as Na
+/H
+
exchange system inhibitor
MIS, MI, angina pectoris WO9813357
Necrosis inhibitor Benzothiophen-2-carbonylguanidine derivatives I/R US2010004466
Necrosis
and
apoptosis
TNF-a inhibitor/antagonist Human recombinant antibodies anti TNF-a MIS WO9729131
TNF-a inhibitor/antagonist Soluble TNF receptor HF WO0059530
TNF-a inhibitor/antagonist Inhibition of TNF-a expression with adenosine CHF US6221851
TNF-a inhibitor/antagonist Inhibition of TNF-a expression with phosphodiesterase
type IV inhibitors
CHF EP0995439
TNF-a inhibitor/antagonist Soluble TNF-a receptor CHF WO02080847
TNF-a inhibitor/antagonist Anti-TNF-a antibodies Heart pathologies
underlying excess TNF-a
US2003180299
TNF-a inhibitor/antagonist Anti-TNFR1 polypeptides based on antibody
single-variable domains
Heart necrosis WO2010081787
TNF-a inhibitor/antagonist Bicyclosulfonyl acid compounds CHF, I/R US2010311741
FAS inhibitor/antagonist Antibody against human FAS MI, MIS, I/R US2010233157
PARP inhibitor 3,6-Substituted 5-arylamino-1H-pyridine-2-one
derivatives
MIS, diabetic myocardial
disease
US2007281948
PARP inhibitor Truncated PPAR inhibitor HF WO2009043953
Apoptosis Caspase inhibitor Nicotinyl aspartyl ketones derivatives such as caspase-
3-inhibiting compounds
I/R WO0127085
Caspase inhibitor Isoxazoline derivatives MIS US6747050
Caspase inhibitor Substituted a-hydroxy acid such as potent inhibitors of
caspases and apoptotic cell death
MI, I/R, CHF, C WO0116093
Caspase inhibitor Protein inhibitor of caspase 3 MIS, conduction
disturbance, chronic heart
diseases
JP2002355077
Caspase inhibitor Inhibitor of caspase 3 or caspase-activated
desoxyribonuclease inhibitor
HF US2003130216
Caspase inhibitor 2-Aminobenzamide derivatives MI, CHF, C US2003181388
Caspase inhibitor Dipeptide derivatives MI, CHF, C US2003181391
Caspase inhibitor Dipeptide derivatives MI, CHF, HF, C US2004116355
Caspase inhibitor Substituted piperidine, tetrahydroquinoline, or
tetrahydroisoquinoline
MIS, MI, CHF, ATH,
coronary artery bypass
graft
WO0190070
Caspase inhibitor Antisense for MIAP1, MIAP2, MIAP3, CIAP1, CIAP2,
XIAP, APAF1, RAIDD, and Diablo/SMAC
Cardiac disorders US2004254136
Caspase inhibitor Cell wall of Chlorella pyrenoidosa MIS JP2005089324
Caspase inhibitor Pyridazinone derivatives MIS WO2008016239
Caspase inhibitor Danshensu derivatives MIS CN101607904
Caspase inhibitor Peptide derivatives MIS US2010184703
Caspase inhibitor Inhibition of OMI/HTRA2 HF, MI US2010311772
Caspase inhibitor Isoxazoline derivative MIS WO2006090997
Intervention of Bcl2-related
proteins
Modiﬁed Bcl-xL MI, I/R WO2004110471
Intervention of Bcl2-related
proteins
Antisense oligonucleotide against BNIP3 Hypoxia-acidosis-
associated cardiac cell
death
WO2004009780
Apoptosis inhibitor 2-Substituted-4H-1,3-benzothiazine-4-one compounds Heart diseases US2003186971
Apoptosis inhibitor Extracts of Radix salviae miltiorrhizae and Rhizoma
cnidii
To inhibit apoptotic cardiac
cell death
KR20040000651
Apoptosis inhibitor 3-[4-(4-Chlorophenyl)piperazin-1-yl]methyl-
1H-pyrrolo[2,3-b]pyridine
MIS, C EP1815866
Apoptosis inhibitor Human FAF1 protein inhibitor MIS, HF, diabetic CVD, H KR100818752
Apoptosis inhibitor Aminothiophene derivatives MIS, diabetic CVD, HF, H WO2008140214
Apoptosis inhibitor Recombinant human ARC protein C, MI, HF CN101307320
Apoptosis inhibitor 1,3-Benzothiazinone Heart disease US2009082343
Apoptosis inhibitor Tetrahydroisoquinolines MI, MIS US2009306130
Apoptosis inhibitor Deletion or silencing of midkine I/R US2010056437
Apoptosis inhibitor Extracts of Gramineae plant MIS US2010068315
Apoptosis inhibitor Corynantheine, the alkaloid extract from Uncaria MIS WO2010043109
Autophagy Autophagy induction 8-Methylchroman-7-ol derivatives ATH, MIS US2010173983
Proteinopathy treatment Farnesyl transferase inhibitor MI, MIS, vascular
hyperplasia, H, CHF,
restenosis, ATH, HT,
angina pectoris,
US2010160372
Autophagy regulation Cell permeable Tat-Atg5K130R (inhibitor of autophagy)
and Tat-Beclin l (activator of autophagy)
HF, I/R WO 2011106684
Autophagy regulation Compounds that regulates ATG14L and rubicon, which
binds class III PI3K/Vps34–Beclin 1 complex
Inﬂammatory cardiac
diseases
WO2010030936
Autophagy induction Glycosylated anti-tumor ether lipids are small
molecules that induce and/or enhance autophagy in
cells
I/R WO2009092170
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MI and HF are associated with signiﬁcant loss of cardiac
myocytes, a process that has been thought to be irreversible.
However, the discovery of tissue resident cardiac stem cells
and the ability of exogenously delivered bone marrow (BM)-
derived stem cells to confer beneﬁt have recently challenged
this long held belief.
77 These discoveries have stimulated
basic and clinical research, with the aim of employing the
regenerative properties of stem cells to repair damaged
myocardium, improve cardiac function, and improve patient
morbidity and mortality.
77
Skeletal muscle cells have been considered as an
alternative cell source for transplantation to improve cardiac
function in animal models, which indeed succeeded. How-
ever, subsequent clinical trials revealed a signiﬁcant signal for
arrhythmic harm.
78 Other types of cells, such as cultured
cardiac stem cells, embryonic stem cells, or induced
pluripotent stem cells, have also been considered as cellular
sources for generating cardiac myocytes.
79 Early reports
showing that BM-derived adult stem/progenitor cells manifest
greater plasticity than expected and can differentiate into
cardiac myocytes raised the hope that BM-derived stem cells
may improve both neovascularization and repair of the
infarcted heart. Although there have been several basic
research and numerous clinical studies showing that different
subpopulations of BM-derived stem cells and other progenitor
cells are capable of enhancing heart function, the signaling
pathwaysinvolved andtheextenttowhichprogenitor cellsare
able to reestablish cardiac function in stage IV HF is
extensively debated.
77,79
Conclusions and Perspectives
Autophagy, apoptosis, and necrosis are major mechanisms in
the pathogenesis of CVD. A summary of interventions
showing the relevance of autophagy, apoptosis, and necrosis
in cardiac myocyte cell death and/or heart diseases is
depicted in Table 1. One day, clinical therapy targeting
myocyte cell death is envisioned. Even though some
translational applications have been tested already, manip-
ulation of cardiac myocyte death is in its infancy. Currently,
55 patent applications related to the control of cardiac
myocyte death/survival (5 in necrosis, 29 in apoptosis, 11 in
apoptosis and/or necrosis, and 10 in autophagy) and its
application to treatment of CVDs have been ﬁled (Table 2).
However, none of these products has emerged with success
in clinical trials. Major translational challenges remain in this
exciting area, but patients with heart disease are likely to
beneﬁt from these efforts.
Conﬂict of Interest
The authors declare no conﬂict of interest.
Acknowledgements. We thank the members from the Hill lab and
Lavandero lab for helpful discussions. This work was supported by grants from the
NIH (HL-075173, JAH; HL-080144, JAH; and HL-090842, JAH), AHA (0640084N,
JAH), the AHA-Jon Holden DeHaan Foundation (0970518N, JAH), and the
Fondo Nacional de Desarrollo Cientiﬁco y Tecnologico: FONDECYT 1080436 and
FONDAP 15010006 (SL). ZVW, ZP, and RT are supported by postdoctoral
fellowships from the American Heart Association 10POST4320009 and
FONDECYT 3110039 and 3110114, respectively.
1. Whelan RS, Kaplinskiy V, Kitsis RN. Cell death in the pathogenesis of heart disease:
mechanisms and signiﬁcance. Annu Rev Physiol 2010; 72: 19–44.
2. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008; 132: 27–42.
3. Marambio P, Toro B, Sanhueza C, Troncoso R, Parra V, Verdejo H et al. Glucose
deprivation causes oxidative stress and stimulates aggresome formation and autophagy in
cultured cardiac myocytes. Biochim Biophys Acta 2010; 1802: 509–518.
4. Lipinski MM, Hoffman G, Ng A, Zhou W, Py BF, Hsu E et al. A genome-wide siRNA screen
reveals multiple mTORC1 independent signaling pathways regulating autophagy under
normal nutritional conditions. Dev Cell 2010; 18: 1041–1052.
5. Matsui Y, Takagi H, Qu X, Abdellatif M, Sakoda H, Asano T et al. Distinct roles of
autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein
kinase and Beclin 1 in mediating autophagy. Circ Res 2007; 100: 914–922.
6. Yan L, Vatner DE, Kim SJ, Ge H, Masurekar M, Massover WH et al. Autophagy in
chronically ischemic myocardium. Proc Natl Acad Sci USA 2005; 102: 13807–13812.
7. French CJ, Taatjes DJ, Sobel BE. Autophagy in myocardium of murine hearts subjected to
ischemia followed by reperfusion. Histochem Cell Biol 2010; 134: 519–526.
8. Hamacher-Brady A, Brady NR, Logue SE, Sayen MR, Jinno M, Kirshenbaum LA et al.
Response to myocardial ischemia/reperfusion injury involves Bnip3 and autophagy.
Cell Death Differ 2007; 14: 146–157.
9. Russell RR, 3rd, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M et al. AMP-activated
protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac
dysfunction, apoptosis, and injury. J Clin Invest 2004; 114: 495–503.
10. Hamacher-Brady A, Brady NR, Gottlieb RA. Enhancing macroautophagy protects against
ischemia/reperfusion injury in cardiac myocytes. J Biol Chem 2006; 281: 29776–29787.
11. Gustafsson AB, Gottlieb RA. Autophagy in ischemic heart disease. Circ Res 2009; 104:
150–158.
12. Ma X, Foyil SR, Hill JA, Diwan A. Impaired autophagosome clearance contributes to
cardiomyocyte death in ischemia-reperfusion injury. Unpublished Results 2011.
Table 2 (Continued)
Type Patent category Therapeutic/Target Remarks Patent number
Autophagy regulation Autophagy modulators identiﬁed by a high-throughput
phenotypic screen
MIS, I/R WO2008122038
Cardiac autophagy death
regulation
siRNA against ANT isoforms, which selectively
regulates autophagic cell death
MIS US20060210535
Autophagy regulation A phosphorus-rapamycin analog, AP23573 Restenosis, ATH, CVD,
cerebral vascular disease,
peripheral vascular disease
US20040073024
Anti-cardiac autophagic
degeneration/death
Long-term administration of a colony-stimulating factor
(G-CSF)
MIS, F, LVR US2006051318
Cardiac atrophy Agent that increases the expression of the runx1 gene
to prevent or decrease cardiac autophagy
Treatment of a heart
condition whereby heart
muscle is destroyed
US2006003959
Abbreviations: ATH, atherosclerosis; C, cardiomyopathy; CHF, congestive heart failure; CVD, cardiovascular disease; F, myocardial ﬁbrosis; HF, heart failure;
HT, hypertension; I/R, ischemia/reperfusion; LVR, left ventricular remodeling; MI, myocardial infarction; MIS, myocardial ischemia; RI, reperfusion injury
Cardiomyocyte death
M Chiong et al
9
Cell Death and Disease13. Buss SJ, Muenz S, Riffel JH, Malekar P, Hagenmueller M, Weiss CS et al. Beneﬁcial
effects of mammalian target of rapamycin inhibition on left ventricular remodeling after
myocardial infarction. J Am Coll Cardiol 2009; 54: 2435–2446.
14. McCormick J, Suleman N, Scarabelli TM, Knight RA, Latchman DS, Stephanou A.
STAT1 deﬁciency in the heart protects against myocardial infarction by enhancing
autophagy. J Cell Mol Med 2011; e-pub ahead of print 29 March 2011; doi: 10.1111/j.
1582-4934.2011.01323.x.
15. DraznerMH,RameJE,MarinoEK,GottdienerJS,KitzmanDW,GardinJMetal.Increased
left ventricular mass is a risk factor for the development of a depressed left ventricular
ejectionfractionwithinﬁveyears:theCardiovascularHealthStudy.JAmCollCardiol2004;
43: 2207–2215.
16. Kostin S, Pool L, Elsasser A, Hein S, Drexler HC, Arnon E et al. Myocytes die by multiple
mechanisms in failing human hearts. Circ Res 2003; 92: 715–724.
17. Cao DJ, Wang ZV, Battiprolu PK, Jiang N, Morales CR, Kong Y et al. Histone deacetylase
(HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy.
Proc Natl Acad Sci USA 2011; 108: 4123–4128.
18. Zhu H, Tannous P, Johnstone JL, Kong Y, Shelton JM, Richardson JA et al. Cardiac
autophagy is a maladaptive response to hemodynamic stress. J Clin Invest 2007; 117:
1782–1793.
19. Shende P, Plaisance I, Morandi C, Pellieux C, Berthonneche C, Zorzato F et al. Cardiac
raptor ablation impairs adaptive hypertrophy, alters metabolic gene expression, and
causes heart failure in mice. Circulation 2011; 123: 1073–1082.
20. Shioi T, McMullen JR, Tarnavski O, Converso K, Sherwood MC, Manning WJ et al.
Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 2003; 107:
1664–1670.
21. Zhang D, Contu R, Latronico MV, Zhang J, Rizzi R, Catalucci D et al. mTORC1 regulates
cardiacfunctionandmyocytesurvivalthrough4E-BP1inhibitioninmice.JClinInvest2010;
120: 556–563.
22. Kushwaha SS, Raichlin E, Sheinin Y, Kremers WK, Chandrasekaran K, Brunn GJ et al.
Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant
recipients. Eur Heart J 2008; 29: 2742–2750.
23. Nakai A, Yamaguchi O, Takeda T, Higuchi Y, Hikoso S, Taniike M et al. The role of
autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress.
Nat Med 2007; 13: 619–624.
24. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control
with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).
Lancet 1998; 352: 854–865.
25. Yin M, van der Horst IC, van Melle JP, Qian C, van Gilst WH, Sillje HH et al. Metformin
improves cardiac function in a nondiabetic rat model of post-MI heart failure. Am J Physiol
2011; 301: H459–H468.
26. Bahro M, Pfeifer U. Short-term stimulation by propranolol and verapamil of cardiac cellular
autophagy. J Mol Cell Cardiol 1987; 19: 1169–1178.
27. Pfeifer U, Fohr J, Wilhelm W, Dammrich J. Short-term inhibition of cardiac cellular
autophagy by isoproterenol. J Mol Cell Cardiol 1987; 19: 1179–1184.
28. Weiss EP, Fontana L. Caloric restriction – powerful protection for the aging heart and
vasculature. Am J Physiol 2011; 301: H1205–H1219.
29. Liao X, Wang X, Gu Y, Chen Q, Chen LY. Involvement of death receptor signaling in
mechanical stretch-induced cardiomyocyte apoptosis. Life Sci 2005; 77: 160–174.
30. Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP et al. Dilated
cardiomyopathy in transgenic mice with cardiac-speciﬁc overexpression of tumor necrosis
factor-a. Circ Res 1997; 81: 627–635.
31. Lee Y, Gustafsson AB. Role of apoptosis in cardiovascular disease. Apoptosis 2009; 14:
536–548.
32. Condorelli G, Morisco C, Stassi G, Notte A, Farina F, Sgaramella G et al. Increased
cardiomyocyte apoptosis and changes in proapoptotic and antiapoptotic genes bax and
bcl-2 during left ventricular adaptations to chronic pressure overload in the rat. Circulation
1999; 99: 3071–3078.
33. Potts MB, Vaughn AE, McDonough H, Patterson C, Deshmukh M. Reduced Apaf-1 levels
in cardiomyocytes engage strict regulation of apoptosis by endogenous XIAP. J Cell Biol
2005; 171: 925–930.
34. Scheubel RJ, Bartling B, Simm A, Silber RE, Drogaris K, Darmer D et al. Apoptotic
pathway activation from mitochondria and death receptors without caspase-3 cleavage
in failing human myocardium: fragile balance of myocyte survival? J Am Coll Cardiol
2002; 39: 481–488.
35. Chua CC, Gao J, Ho YS, Xiong Y, Xu X, Chen Z et al. Overexpression of IAP-2 attenuates
apoptosis and protects against myocardial ischemia/reperfusion injury in transgenic mice.
Biochim Biophys Acta 2007; 1773: 577–583.
36. Bhuiyan MS, Fukunaga K. Inhibition of HtrA2/Omi ameliorates heart dysfunction
following ischemia/reperfusion injury in rat heart in vivo. Eur J Pharmacol 2007; 557:
168–177.
37. Holly TA, Drincic A, Byun Y, Nakamura S, Harris K, Klocke FJ et al. Caspase inhibition
reduces myocyte cell death induced by myocardial ischemia and reperfusion in vivo. JM o l
Cell Cardiol 1999; 31: 1709–1715.
38. Bahi N, Zhang J, Llovera M, Ballester M, Comella JX, Sanchis D. Switch from caspase-
dependent to caspase-independent death during heart development: essential role
of endonuclease G in ischemia-induced DNA processing of differentiated cardiomyocytes.
J Biol Chem 2006; 281: 22943–22952.
39. Bae S, Siu PM, Choudhury S, Ke Q, Choi JH, Koh YY et al. Delayed activation of caspase-
independent apoptosis during heart failure in transgenic mice overexpressing caspase
inhibitor CrmA. Am J Physiol 2010; 299: H1374–H1381.
40. Gustafsson AB, Tsai JG, Logue SE, Crow MT, Gottlieb RA. Apoptosis repressor with
caspase recruitment domain protects against cell death by interfering with Bax activation.
J Biol Chem 2004; 279: 21233–21238.
41. Daugas E,SusinSA,ZamzamiN,FerriKF,IrinopoulouT,LarochetteNetal.Mitochondrio-
nuclear translocation of AIF in apoptosis and necrosis. FASEB J 2000; 14: 729–739.
42. Joza N, Susin SA, Daugas E, Stanford WL, Cho SK, Li CY et al. Essential role of
the mitochondrial apoptosis-inducing factor in programmed cell death. Nature 2001; 410:
549–554.
43. van Empel VP, Bertrand AT, van der Nagel R, Kostin S, Doevendans PA, Crijns HJ et al.
Downregulation of apoptosis-inducing factor in harlequin mutant mice sensitizes the
myocardium to oxidative stress-related cell death and pressure overload-induced
decompensation. Circ Res 2005; 96: e92–e101.
44. Chen M, Zsengeller Z, Xiao CY, Szabo C. Mitochondrial-to-nuclear translocation
of apoptosis-inducing factor in cardiac myocytes during oxidant stress: potential role of
poly(ADP-ribose) polymerase-1. Cardiovasc Res 2004; 63: 682–688.
45. Parra V, Verdejo H, Del CA, Pennanen C, Kuzmicic J, Iglewski M et al. The complex
interplay between mitochondrial dynamics and cardiac metabolism. J Bioenerg Biomembr
2011; 43: 47–51.
46. Kuzmicic J, del Campo A, Lopez-Crisosto C, Morales PE, Pennanen C, Bravo-Sagua R
et al. Mitochondrial dynamics: a potential new therapeutic target for heart failure. Rev Esp
Cardiol 2011; 64: 916–923.
47. Parra V, Eisner V, Chiong M, Criollo A, Moraga F, Garcia A etal. Changes in mitochondrial
dynamics during ceramide-induced cardiomyocyte early apoptosis. Cardiovasc Res 2008;
77: 387–397.
48. MinaminoT,Komuro I,Kitakaze M. Endoplasmic reticulumstressas a therapeutic target in
cardiovascular disease. Circ Res 2010; 107: 1071–1082.
49. Fu HY, Okada K, Liao Y, Tsukamoto O, Isomura T, Asai M et al. Ablation of C/EBP
homologous protein attenuates endoplasmic reticulum-mediated apoptosis and cardiac
dysfunction induced by pressure overload. Circulation 2010; 122: 361–369.
50. van Empel VP, Bertrand AT, Hofstra L, Crijns HJ, Doevendans PA, De Windt LJ. Myocyte
apoptosis in heart failure. Cardiovasc Res 2005; 67: 21–29.
51. Mani K. Programmed cell death in cardiac myocytes: strategies to maximize post-ischemic
salvage. Heart Fail Rev 2008; 13: 193–209.
52. WenckerD, Chandra M,Nguyen K,Miao W,GarantziotisS,FactorSM etal. Amechanistic
role for cardiac myocyte apoptosis in heart failure. J Clin Invest 2003; 111: 1497–1504.
53. Kajstura J, Cheng W, Reiss K, Clark WA, Sonnenblick EH, Krajewski S etal. Apoptotic and
necrotic myocyte cell deaths are independent contributing variables of infarct size in rats.
Lab Invest 1996; 74: 86–107.
54. Fliss H, Gattinger D.Apoptosis in ischemic andreperfusedrat myocardium. CircRes 1996;
79: 949–956.
55. Nakamura T, Ueda Y, Juan Y, Katsuda S, Takahashi H, Koh E. Fas-mediated apoptosis
in adriamycin-induced cardiomyopathy in rats: in vivo study. Circulation 2000; 102:5 7 2 – 5 7 8 .
56. Lee P, Sata M, Lefer DJ, Factor SM, Walsh K, Kitsis RN. Fas pathway is a critical mediator
of cardiac myocyte death and MI during ischemia-reperfusion in vivo. Am J Physiol 2003;
284: H456–H463.
57. Kurrelmeyer KM, Michael LH, Baumgarten G, Taffet GE, Peschon JJ, Sivasubramanian N
et al. Endogenous tumor necrosis factor protects the adult cardiac myocyte against
ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl
Acad Sci USA 2000; 97: 5456–5461.
58. Chen Z, Chua CC, Ho YS, Hamdy RC, Chua BH. Overexpression of Bcl-2 attenuates
apoptosisandprotectsagainstmyocardialI/Rinjuryintransgenicmice.AmJPhysiol2001;
280: H2313–H2320.
59. Hochhauser E, Cheporko Y, Yasovich N, Pinchas L, Offen D, Barhum Y et al. Bax
deﬁciency reduces infarct size and improves long-term function after myocardial infarction.
Cell Biochem Biophys 2007; 47: 11–20.
60. Toth A, Jeffers JR, Nickson P, Min JY, Morgan JP, Zambetti GP et al. Targeted deletion
of Puma attenuates cardiomyocyte death and improves cardiac function during ischemia-
reperfusion. Am J Physiol 2006; 291: H52–H60.
61. Balakumar P, Singh M. Anti-tumour necrosis factor-a therapy in heart failure: future
directions. Basic Clin Pharmacol Toxicol 2006; 99: 391–397.
62. BozkurtB,Torre-AmioneG,WarrenMS,WhitmoreJ,SoranOZ,FeldmanAMetal.Results
of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with
advanced heart failure. Circulation 2001; 103: 1044–1047.
63. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS et al. Targeted
anticytokine therapy in patients with chronic heart failure: results of the Randomized
Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004; 109: 1594–1602.
64. Kadokami T, Frye C, Lemster B, Wagner CL, Feldman AM, McTiernan CF. Anti-tumor
necrosis factor-a antibody limits heart failure in a transgenic model. Circulation 2001; 104:
1094–1097.
65. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind,
placebo-controlled, pilot trial of inﬂiximab, a chimeric monoclonal antibody to tumor
necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-
TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107:
3133–3140.
Cardiomyocyte death
M Chiong et al
10
Cell Death and Disease66. Bergman MR, Holycross BJ. Pharmacological modulation of myocardial tumor necrosis
factor a production by phosphodiesterase inhibitors. J Pharmacol Exp Ther 1996; 279:
247–254.
67. Sliwa K, Woodiwiss A, Candy G, Badenhorst D, Libhaber C, Norton G et al. Effects of
pentoxifylline on cytokine proﬁles and left ventricular performance in patients with
decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy.
Am J Cardiol 2002; 90: 1118–1122.
68. Vanlangenakker N, Vanden Berghe T, Krysko DV, Festjens N, Vandenabeele P.
Molecular mechanisms and pathophysiology of necrotic cell death. Curr Mol Med 2008; 8:
207–220.
69. Henriquez M, Armisen R, Stutzin A, Quest AF. Cell death by necrosis, a regulated way to
go. Curr Mol Med 2008; 8: 187–206.
70. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death.
Physiol Rev 2007; 87: 99–163.
71. Guerra S, Leri A, Wang X, Finato N, Di Loreto C, Beltrami CA et al. Myocyte death in the
failing human heart is gender dependent. Circ Res 1999; 85: 856–866.
72. Nakayama H, Chen X, Baines CP, Klevitsky R, Zhang X, Zhang H et al. Ca
2+- and
mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure.
J Clin Invest 2007; 117: 2431–2444.
73. Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA et al. Loss of
cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death.
Nature 2005; 434: 658–662.
74. Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata H et al.
Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but
not apoptotic cell death. Nature 2005; 434: 652–658.
75. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N et al. Effect of cyclosporine on
reperfusion injury in acute myocardial infarction. N Engl J Med 2008; 359: 473–481.
76. Lim SY, Davidson SM, Mocanu MM, Yellon DM, Smith CC. The cardioprotective effect of
necrostatin requires the cyclophilin-D component of the mitochondrial permeability
transition pore. Cardiovasc Drugs Ther 2007; 21: 467–469.
77. Mozid AM, Arnous S, Sammut EC, Mathur A. Stem cell therapy for heart diseases.
Br Med Bull 2011; 98: 143–159.
78. Menasche P, Alﬁeri O, Janssens S, McKenna W, Reichenspurner H, Trinquart L et al. The
Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: ﬁrst randomized
placebo-controlled study of myoblast transplantation. Circulation 2008; 117: 1189–1200.
79. Laﬂamme MA, Murry CE. Heart regeneration. Nature 2011; 473: 326–335.
80. Hochhauser E, Kivity S, Offen D, Maulik N, Otani H, Barhum Y et al. Bax ablation protects
against myocardialischemia-reperfusioninjury intransgenicmice.AmJPhysiol 2003;284:
H2351–H2359.
81. de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A et al. Association of
troponin T detected with a highly sensitive assay and cardiac structure and mortality risk
in the general population. JAMA 2010; 304: 2503–2512.
Cell Death and Disease is an open-access journal
published by Nature Publishing Group. This work is
licensed under the Creative Commons Attribution-Noncommercial-No
DerivativeWorks3.0UnportedLicense. To view acopyof thislicense,
visit http://creativecommons.org/licenses/by-nc-nd/3.0/
Cardiomyocyte death
M Chiong et al
11
Cell Death and Disease